Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UKV8

UPID:
AGO2_HUMAN

ALTERNATIVE NAMES:
Argonaute RISC catalytic component 2; Eukaryotic translation initiation factor 2C 2; PAZ Piwi domain protein; Protein slicer

ALTERNATIVE UPACC:
Q9UKV8; Q8TCZ5; Q8WV58; Q96ID1

BACKGROUND:
Protein argonaute-2, recognized for its roles in gene silencing mechanisms, is crucial for the function of the RNA-induced silencing complex (RISC). It binds to microRNAs and short interfering RNAs, directing RISC to silence target mRNAs through cleavage or translational inhibition. Its involvement in various cellular processes, including response to viral infections like Sars-CoV-2, positions it as a key player in cellular defense and gene regulation.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Lessel-Kreienkamp syndrome, characterized by intellectual disability and developmental delay, Protein argonaute-2 presents a promising target for therapeutic intervention. Exploring the functions and mechanisms of Protein argonaute-2 could lead to innovative treatments for this and potentially other genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.